Scrip Asia 100 - S*BIO sticks to the book on its road to market
This article was originally published in Scrip
Thanks to healthy income from licensing partners, S*BIO is in the enviable position of being able to plan carefully both its strategy for internal R&D and future financing. The attractions of Singapore have also helped S*BIO to recruit a surprisingly international workforce, Dr Jan-Anders Karlsson, the bioventure's CEO, tells Ian Haydock.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.